NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Repare Therapeutics Inc. (RPTX) Stock Analysis

Repare Therapeutics Inc. (RPTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RPTX

$2.65

$0.00 (0.00%)

Last trade January 28, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RPTX with… →

RPTX Key Statistics

As of Jan 28, 2026
Trading
Open
$2.65
Previous Close
$2.65
52-Week Range
0.89–2.66
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$114.24M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.70
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+130.43%
Dividend and dates
Avg Volume
1.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RPTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.92%
2025+98.47%
2024 (partial year)−0.76%

As of January 28, 2026.

RPTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRPTXBiotechnology medianvs median
P/S ratio9.6215.2637% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Repare Therapeutics Inc. (RPTX) at $114.24M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 129 employees.

Over the past 52 weeks the price has ranged from $0.89 to $2.66. RPTX last closed at $2.65 on January 28, 2026. The close was unchanged from the previous session. The latest close sits 197.75% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $11.87M. The reported profit margin is 0%. Trailing earnings per share are −1.7.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 9.62 times revenue. On price-to-sales that is 36.95% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +130.43%. The reported beta is 0.96. Daily returns over the trailing 1 year annualize to a volatility of 59.91%.

Growth & Income

The record shows no dividend for RPTX.

So far in 2026 the price is +1.92%. The record holds one complete calendar year, 2025, which returned +98.47%.

Peer Comparison

Repare Therapeutics Inc. (RPTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Repare Therapeutics Inc. RPTX $114.24M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Repare Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of January 28, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Repare Therapeutics Inc.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.

Visit website →